Opinion|Videos|January 27, 2025
Treatment Options for Tardive Dyskinesia
Panelists discuss how VMAT2 inhibitors deutetrabenazine and valbenazine have revolutionized TD treatment through their proven efficacy in reducing involuntary movements and favorable safety profiles, with clinical trials demonstrating significant symptom improvement as measured by AIMS scores while maintaining psychiatric stability and showing key differences in dosing schedules and titration approaches.
Advertisement
Episodes in this series
Video series above is prompted by the following:
- Please provide an overview of the pharmacological treatment options currently available for patients with TD, highlighting their safety and efficacy.
- Deutetrabenazine
- Valbenazine
Advertisement
Related to this article
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Phase 3 data show pembrolizumab beats chemotherapy, offering durable first-line control with fewer severe toxicities and chemo-free potential.
From insurance delays to injection concerns, pharmacists can help patients navigate the first month and avoid preventable treatment interruptions.
In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, discusses NCCN breast cancer guideline updates involving ESR1 mutation testing, targeted therapies, and pharmacists’ roles in monitoring, patient counseling, and treatment access.
Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.
Specialty pharmacy liaisons improve breast cancer care by easing access barriers, managing side effects, boosting adherence, and navigating new therapies and policies.
Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
Advertisement
Advertisement
Trending on Pharmacy Times
1
PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease
2
Walgreens Adds Pharmacist Outreach, Coverage Help for GLP-1s
3
GLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKD
4
The Growing Role the Specialty Pharmacy Team Plays in Helping Breast Cancer Patients Navigate Treatment
5